Zacks Research Weighs in on NewGenIvf Group FY2026 Earnings

NewGenIvf Group Limited (NASDAQ:NIVF) – Equities research analysts at Zacks Research issued their FY2026 earnings per share (EPS) estimates for shares of NewGenIvf Group in a research note issued to investors on Wednesday, April 1st. Zacks Research analyst B. Sorensen anticipates that the company will post earnings per share of $4.74 for the year. Zacks Research also issued estimates for NewGenIvf Group’s FY2027 earnings at $9.34 EPS and FY2028 earnings at $14.70 EPS.

Other research analysts also recently issued research reports about the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of NewGenIvf Group in a research note on Wednesday, January 28th. Wall Street Zen raised shares of NewGenIvf Group to a “hold” rating in a research report on Saturday, December 6th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

NewGenIvf Group Price Performance

Shares of NewGenIvf Group stock opened at $2.13 on Friday. The business has a 50-day simple moving average of $3.10 and a 200-day simple moving average of $30.80. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.43 and a quick ratio of 3.37. NewGenIvf Group has a one year low of $1.52 and a one year high of $4,440.00.

NewGenIvf Group Company Profile

NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.

NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.